These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22024966)

  • 1. Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.
    Yang SH; Kuo YH; Tien YW; Hsu C; Hsu CH; Kuo SH; Cheng AL
    Oncology; 2011; 81(3-4):143-50. PubMed ID: 22024966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
    Gill S; Ko YJ; Cripps C; Beaudoin A; Dhesy-Thind S; Zulfiqar M; Zalewski P; Do T; Cano P; Lam WYH; Dowden S; Grassin H; Stewart J; Moore M
    J Clin Oncol; 2016 Nov; 34(32):3914-3920. PubMed ID: 27621395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
    Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Wagner AD; Buechner-Steudel P; Wein A; Schmalenberg H; Lindig U; Moehler M; Behrens R; Kleber G; Kuss O; Fleig WE
    Ann Oncol; 2007 Jan; 18(1):82-87. PubMed ID: 17030546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
    J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
    Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C
    J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
    Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
    Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
    Sohal DP; Metz JM; Sun W; Giantonio BJ; Plastaras JP; Ginsberg G; Kochman ML; Teitelbaum UR; Harlacker K; Heitjan DF; Feldman MD; Drebin JA; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1485-91. PubMed ID: 23532207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
    Reni M; Cereda S; Bonetto E; Viganò MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):361-7. PubMed ID: 16807732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
    Hess V; Pratsch S; Potthast S; Lee L; Winterhalder R; Widmer L; Cescato C; Lohri A; Jost L; Stillhart P; Pestalozzi B; Herrmann R
    Ann Oncol; 2010 Dec; 21(12):2390-2395. PubMed ID: 20444846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
    Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
    Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
    El-Hadaad HA; Wahba HA
    J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katopodis O; Souglakos J; Stathopoulos E; Christopoulou A; Kontopodis E; Kotsakis A; Kalbakis K; Kentepozidis N; Polyzos A; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):333-40. PubMed ID: 24930058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
    Tsang ES; Spratlin J; Cheung WY; Kim CA; Kong S; Xu Y; Gill S
    Am J Clin Oncol; 2019 Dec; 42(12):903-908. PubMed ID: 31693510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
    Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS
    Oncology; 2009; 76(5):333-7. PubMed ID: 19307739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
    Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
    Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
    Ohkawa S; Okusaka T; Isayama H; Fukutomi A; Yamaguchi K; Ikeda M; Funakoshi A; Nagase M; Hamamoto Y; Nakamori S; Tsuchiya Y; Baba H; Ishii H; Omuro Y; Sho M; Matsumoto S; Yamada N; Yanagimoto H; Unno M; Ichikawa Y; Takahashi S; Watanabe G; Wakabayashi G; Egawa N; Tsuda M; Hosotani R; Hamada C; Hyodo I
    Br J Cancer; 2015 Apr; 112(9):1428-34. PubMed ID: 25880004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.